Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Enzychem Files IND for Phase 2 Study of EC-18 in Preventing ARDS Due to COVID-19 Pneumonia

americanpharmaceuticalreviewJuly 22, 2020

Tag: COVID-19 , Enzychem Lifesciences , EC-18 , pneumonia , ARDS

PharmaSources Customer Service